Lovenox Generics Might Be Slowed In U.S. Because Of EU Guidance, Sanofi Hopes
Executive Summary
Sanofi-Aventis says an emerging European guideline prescribing clinical trials for low molecular weight heparin generics could sway FDA as it considers copies of its clot-busting blockbuster Lovenox
You may also be interested in...
Generic Lovenox In EU Will Require Clinical Data, Shrinking Sandoz’s Opportunity
An EU guidance issued earlier this year requiring clinical trials for generic copies of low molecular weight heparins may just have shot the European market opportunity for Momenta and its partner Sandoz, according to Momenta's CFO Rick Shea
Biogenerics Get A Low Score From CBO, But Is BIO Actually The Loser?
The reaction of stakeholders to the Congressional Budget Office's score of potential savings from follow-on biologics illustrates the challenges for the various players as debate on legislation continues
Sanofi Loses Another Lovenox Round
“All options” under review in legal battle against generics.